Compare USNA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | EYPT |
|---|---|---|
| Founded | 1992 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.1M | 1.5B |
| IPO Year | 1996 | 2005 |
| Metric | USNA | EYPT |
|---|---|---|
| Price | $17.34 | $13.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 130.8K | ★ 1.7M |
| Earning Date | 05-18-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,060,902,000.00 | $7,539,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $6.22 | $965.51 |
| P/E Ratio | $25.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.80 | $3.91 |
| 52 Week High | $38.32 | $19.11 |
| Indicator | USNA | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 29.52 | 35.42 |
| Support Level | N/A | $11.88 |
| Resistance Level | $21.35 | $14.24 |
| Average True Range (ATR) | 0.70 | 1.16 |
| MACD | -0.32 | -0.43 |
| Stochastic Oscillator | 8.60 | 0.17 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.